Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for Chemotherapy-Induced Thrombocytopenia in Multiple Myeloma
NCT01676961Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Jan 2013
- Primary completion
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by NYU Langone Health. Started Jan 2013; status: terminated.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT01676961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01676961.